Transcript Highlights:

• You are the president of the Texas Trial Lawyers Association testifying on behalf of the Texas Trial
• We have the trial lawyers complaining about this.
• I work in clinical practice, so I can't pick up.
• , there's clinical recognition.
• Hospital physician clinics.

Bills: HB46 , HB35 , HB4490 , HB4454 , HB2188 , HB3078 , HB4743 , HB2556 , HB46 , HB5342 , HB4783 , HB3785 , HB5278 , HB1639 , HB2581 , HB4224 , HB4070 , HB4099 , HB4882 , HB3794

Committee: House Public Health

Keywords: local government spending cap, expenditure limit, political subdivision, property tax, ad valorem tax, budget cap, taxpayer protection, spending restraint, inflation adjustment, population growth, voter approval, supermajority vote, county budget, municipal budget, school district finance, junior college district, hospital district, special district, attorney general enforcement, local fiscal limits

Transcript Highlights:

• Biopharma needs that type of nondilutive funding for clinical trials and for research, and that has been
• Our role in health care is one that will always rely on the clinical level.
• I can't bring something to the market without doing the clinical trial.
• in clinical studies.
• So it's an adaptive clinical pathway that we're looking at with the FDA.

Keywords: 988, house, all

Transcript Highlights:

• At the time, there was not the adequate research, clinical studies, that had been completed since then
• Since that passage, there's been over 28 clinical trials completed.
• </c><00:03:23.640><c> trials</c><00:03:24.200><c> completed.
• </c><00:03:25.400><c> There's</c> 28 clinical trials completed.
• There's 28 clinical trials completed.

Committee: Senate Veterans, Military Affairs, & Public Protection

Keywords: 958, all

Transcript Highlights:

• You'll note that there's a thing on U of M drug trial monitoring.
• Some years ago there was a controversy over informed consent in some drug trials involving juveniles,
• monitoring some years ago ofm drug trial monitoring some years ago there<00:25:49.279><c> was</c><00
• </c> un University of Minnesota drug trials un University of Minnesota drug trials for<00:26:05.760><
• Chair, members, the assessment is on the clinical side of things.

Committee: House Human Services Finance and Policy

Keywords: 1183, house

Transcript Highlights:

• Different agents being studied, much of these in Arizona, over 180 different clinical trials.
• That clinical trial would... So I entered into a clinical trial.
• That clinical trial was for the drug that they were just talking about, lecanemab.
• I continued with the clinical trial, and that led to FDA approvals, not only the trial drug, but diagnosis
• Not everyone can be in a clinical trial.

Bills: HB2190 , HB2202 , HB2233 , HB2251 , HB2252 , HB2396 , HB2437 , HB2689 , HB2796

Committee: House Health & Human Services

Keywords: physician assistants, licensure compact, medical services, multistate practice, patient care access, healthcare workforce, military families, adverse actions, dementia care, telementoring, healthcare education, rural communities, grant funding, HB 2233, rural health transformation, rural health transformation program, AHCCCS, Arizona Health Care Cost Containment System, Joint Legislative Budget Committee, JLBC

Transcript Highlights:

• I could see a controlled trial.
• </c><01:03:38.599><c> trials</c><01:03:38.960><c> and</c><01:03:39.119><c> you</c> when you look at clinical
• trials and you when you look at clinical trials and you look<01:03:39.319><c> at</c><01:03:39.480><c
• </c><01:48:45.679><c> social</c> independently licensed clinical social independently licensed clinical
• </c> for you too I I know the Mayo Clinic for you too I I know the Mayo Clinic studies<02:05:57.239><

Committee: House Health, Human Services & Elderly Affairs

Keywords: 1189, house, all

Transcript Highlights:

• We want to provide precision cancer testing and access to clinical trials right there in your hometown
• </c><00:58:17.040><c> trials</c> testing and access to clinical trials testing and access to clinical
• <00:58:41.120><c> trials</c><00:58:41.720><c> are</c><00:58:41.880><c> available,</c> clinical trials
• </c><01:07:33.160><c> And</c><01:07:33.240><c> we</c> patients with clinical trials.
• And we patients with clinical trials.

Keywords: 958, all

Summary: The committee opened its sixth and final interim meeting with roll call, quorum confirmation, approval of the prior minutes, and a brief change in agenda order to preserve quorum and accommodate presenters’ schedules. Members then moved through several proposed health-related items with limited discussion, and the chair noted the committee would reconvene in January for further conversation. The first substantive item was a proposal relating to utilization controls for non-opioid analgesics in Medicaid. Senator Gerald Neal and Tara Hyde of People Advocating Recovery argued that pain parity is needed so patients can access non-opioid options without prior authorization or step therapy barriers, especially in acute pain situations and for people in recovery. Senator Berg supported the concept and suggested expanding the approach to other prescriptions by allowing physicians to explain why step therapy is inappropriate at the time of prescribing; another member cautioned against unintended cost increases if non-opioid drugs are used as add-ons to opioids. The committee then heard a proposal on physician assistants from Senator Scott and Andrew Rutherford of the Kentucky Academy of Physician Assistants. They described a shift from a supervisory to a collaborative practice model, with practice scope set at the practice level, limited Schedule II prescribing authority under guardrails, and permission for PAs to perform driver’s license vision testing. Supporters said the changes would improve rural access, reduce administrative burden, and align Kentucky with neighboring states; a question from Representative Bratcher focused on experience requirements and how the proposal compares with nurse practitioner rules. No vote was taken. Finally, Representative Nancy Tate, Adia Wuchner, and Representative Jason Nemes introduced a 2026 proposal aimed at “protecting vulnerable people.” They described a broad package focused on abortion pill trafficking, marketing to minors, commercial surrogacy, assisted suicide, and organ procurement safeguards, arguing that current law leaves gaps and that additional criminal and civil penalties are needed. The presentation was informational only, with no action taken before the meeting ended.

Transcript Highlights:

• There are public clinical reports... ...many other clinical manifestations.
• Overdose implies also that it can be prescribed in clinical trials and that.
• When you have a substance that hasn't undergone clinical trials to establish safety, where it goes from
• That claim is based on zero clinical trials and zero observational studies.
• Madam Chair, you asked us last year for clinical research on 7-0, and we listened.

Committee: Senate Health

Keywords: 987, senate, all

Transcript Highlights:

• I'm Goha Reza, I'm a geriatrician and director of the Memory Clinic at UAMS.
• We now have oncology clinics providing amyloid PETs, but that’s happened because of the revolution or
• We now have blood tests that are being used in specialty clinics as a triage to qualify patients for
• significant ones on risk here domestically, because as you look at the participants in the disease trial
• significant ones on risk here domestically, because as you look at the participants in the disease trial

Committee: All ALZHEIMER'S DISEASE AND DEMENTIA ADVISORY COUNCIL

Summary: The Arkansas Alzheimer’s Disease and Dementia Advisory Council met with legislative members and agency, advocacy, and provider representatives present. The council adopted its rules and procedures, approved the prior meeting minutes, and authorized the co-chairs to approve special expenses. Members then heard an extensive update on the state Alzheimer’s plan and current developments in diagnosis, treatment, research, caregiving, and workforce issues. David Cook of the Alzheimer’s Association described major changes since the first state plan, including the growth of blood-based biomarkers, broader access to amyloid PET scans, and the availability of disease-slowing treatments such as Leqembi and Kisunla. He emphasized that Arkansas still faces major barriers in rural areas, including limited provider awareness, insurance coverage concerns, shortages of specialists, and long wait times for memory care and infusion services. He also highlighted caregiver burden, the need for better education and care navigation, and new efforts such as a dementia resource center pilot with UAMS, respite grants, and workforce training. Members discussed the importance of public education on brain health, diet, exercise, and risk reduction, as well as the need to collaborate with chronic disease partners and improve outreach to primary care providers. The council approved four proposed focus areas for the next state plan: advancing risk reduction, brain health, early detection and diagnosis; strengthening family caregiver support; improving access to diagnostics and treatment; and supporting access and quality of care, including workforce training and crisis response. Members also discussed possible legislative or statutory changes to keep the council active and engaged, and they agreed to pursue a future meeting in August, tentatively August 12 in Hot Springs, with additional meetings under consideration for later in the month. The meeting adjourned after no further business.

Transcript Highlights:

• Pre-trial detention needs to be addressed.
• clinic.
• I want to talk a little bit about the clinics that have closed. I do wish, Mr.
• Clinics to be able to receive the funds first. The reason being, Mr.
• Albuquerque area clinic. Mr.

Transcript Highlights:

• Biopharma needs that type of non-dilutive funding for clinical trials and for research, and that has
• I can't bring something to the market without doing the clinical trial.
• That correlated with how the patient's doing clinically is really what we're pointing to in clinical
• So it's an adaptive clinical pathway that we're looking at with the FDA.
• So it's an adaptive clinical pathway that we're looking at with the FDA. adaptive clinical pathway that

Summary: The Assembly Select Committee on Biotechnology and Medical Technology held a hearing on California’s medical technology landscape, with opening remarks emphasizing the sector’s size, economic impact, and role in jobs and innovation. The first panel contrasted MedTech with biopharma, describing MedTech as hardware- and manufacturing-oriented, more incremental in development, and more dependent on supply chains, land use, and mid-skilled workforce pipelines. Witnesses argued California is the epicenter for MedTech because of its mix of engineering, software, hospitals, and manufacturing ecosystems, and cited clusters in places like Irvine, Fremont, Carlsbad, and the Bay Area. They also highlighted examples such as Penumbra and Vyaire Medical Systems to show how local manufacturing, community college training, and reshoring can support growth. The panel discussed cybersecurity, trade relations, supply chain disruptions, and the need for better coordination with hospitals and regulators, while AdvaMed stressed that medical devices are already heavily regulated by the FDA and should generally be exempt from broader state laws that could create a patchwork of requirements. Members also discussed AI in MedTech, workforce training, and the possible effects of federal NIH funding cuts, with witnesses saying MedTech is less dependent on NIH than biopharma but still benefits from a strong innovation ecosystem. Committee members then asked about AI, affordability, patient satisfaction, women’s health, and the R&D tax credit. Witnesses said AI is helping reduce errors, redundant testing, and imaging time, while keeping clinicians in the loop, and that digital pathology and robotic surgery are improving diagnosis and treatment. They also noted that packaging, plastics, and recycling can affect FDA approvals, and that FemTech is an active and growing area for investment and acquisition. Several members raised concerns about California’s regulatory and incentive environment, including the loss of the R&D tax credit, and witnesses said the absence of tax incentives has made it harder to keep companies and jobs in the state. The second panel featured company representatives from Lyca Biosystems, Intuitive, Saravia Neurosciences, and Newman. Dr. Monroe described digital pathology as a way to digitize tissue slides, improve access to subspecialty review, and enable AI-assisted diagnosis, especially for cancer care and rural areas. Intuitive highlighted robotic-assisted surgery, including the da Vinci system and the Ion bronchoscopy platform, and said its technologies improve precision, reduce complications, and support clinician-led care. Saravia Neurosciences presented an early-stage neurotechnology for dementia that uses MRI-guided transcranial magnetic stimulation and AI-driven personalization, and argued California needs a state translational fund to bridge the gap between discovery and commercialization. Newman, a startup working on home diagnostics, said California’s permitting, zoning, and manufacturing rules make it difficult to scale advanced manufacturing locally and urged streamlining, reduced red tape, and incentives to keep manufacturing jobs in-state. Committee members again focused on tax credits and asked how the state could better support manufacturing, translational funding, and the retention of high-paying MedTech jobs.

Transcript Highlights:

• Ian Kim, who is a family physician at Davis Community Clinic, an assistant clinical professor at UC Davis
• trial. ...advisory panel to apply directly to the FDA for a multi-site clinical trial of psilocybin,
• Unlike most clinical trials, this one will enroll veterans with overlapping conditions: PTSD, depression
• trials.
• Currently, several dozen psychedelic clinical trials are being conducted in this country, and there is

Summary: The Assembly Health Committee heard a long agenda of health-related bills, beginning with AB 2651 by Bonta, which would require schools to notify parents when school vaccination rates fall below herd immunity thresholds. Supporters, including family physicians, PTA representatives, and medical groups, said the bill would improve transparency and help parents protect children and vulnerable family members. Opponents argued the data could be misleading, could identify medically exempt or conditional students, and might lead to stigma or discrimination. The bill was later moved out of committee on a due-pass-as-amended motion, with one no vote recorded on the roll call. The committee also heard AB 2123 by Aguirre-Curry on medical debt relief, AB 1570 by Wilson to eliminate out-of-pocket costs for medically necessary breast diagnostic and supplemental imaging, AB 2201 by Berner to restore Medi-Cal eligibility and renewal flexibilities, AB 2448 by Berman to strengthen privacy protections for reproductive and gender-affirming care records, AB 2034 by Addis on food additive safety and transparency, and AB 2598 by Krell to require better notification of next of kin when a patient dies in a hospital. Each bill drew strong support from authors, advocates, and affected individuals, while some drew opposition from insurers, industry groups, or transparency critics who raised concerns about cost, duplication, implementation, or unintended harm. Several bills were moved forward on due-pass-as-amended motions, including AB 2123, AB 2201, AB 2448, AB 2034, and AB 2598. The committee also heard AB 2551 by Elhawary, which would require health plans to collect and publish data on how often enrollees must go out of network for behavioral health care and why. Supporters said the measure would expose access barriers and high out-of-pocket costs, especially for communities of color and people with language access needs; opponents said it would add another reporting mandate and might not solve provider shortage problems. Members generally expressed support for the bill’s goals and several described personal or district-level experiences with behavioral health access problems. The bill was then moved out of committee on a due-pass motion. The committee also took up consent items and other procedural motions, with multiple bills reported out and some placed on call.

Transcript Highlights:

• SB 984 adds additional aggravating factors for consideration during capital trials and sentencing.
• When a capital felony is committed, the trial is typically divided into two phases.
• I am a student at Florida State University earning my master's in clinical social work.
• I am a student at Florida State University earning my master's in clinical social work.
• “So you were saying that line 70 to 72 somehow would bring in abortion clinics?”

Summary: The committee heard and voted on a long agenda of criminal justice, public safety, and civil justice bills. Among the measures reported favorably were SB 984, which adds aggravating factors for capital sentencing when a murder occurs during religious, school, or public government gatherings; SB 1140, creating a Hillsborough County pilot program to address substance abuse among offenders on probation; SB 1180, expanding child pornography laws to cover lewd altered or filtered images and solicitation; SB 10, providing compensation to Sidney Holmes for a wrongful conviction; SB 500, creating a Spectrum Alert system and training for missing children with autism; SB 1054, increasing penalties for tampering with electronic monitoring devices; SB 1072, establishing an expedited DNA testing grant program; and SB 240, the Haven Act, which aligns domestic and dating violence protections and creates a feasibility study for a discreet emergency contact system for victims. Several bills were amended before passage, including funding for the Spectrum Alert program and technical changes to the DNA, juvenile justice, and other proposals. Members also advanced SB 494, creating a statewide FDLE animal abuse database and increasing sentencing consequences for aggravated animal cruelty, with strong support from animal welfare groups and county officials. SB 1422 was reported favorably to strengthen penalties for unmanned aircraft over critical infrastructure and for weaponized drones, though members raised concerns about the bill’s “reasonable force” language. SB 1268 updated FDLE statutes and increased reimbursement for retired police dogs. SB 1252 was amended into a feasibility study for a statewide pawn data database, and SB 1386 increased penalties for assaults and batteries on utility workers, drawing support from utility and industry groups. The committee also approved SB 1084 on sexual cyber harassment, which criminalizes dissemination of intimate images and digitally forged intimate images, and SB 1654, which revises sexual offender and predator registration rules, including online reporting for certain in-state travel residences. SB 1650 expanded the vexatious litigant law, and SB 1652 created a public records exemption for stricken non-criminal court filings. Finally, SB 1284, expanding Florida’s Wrongful Death Act to allow civil claims for the death of an unborn child, drew extensive testimony both for and against; supporters called it a life-affirming measure, while opponents warned it could increase litigation, affect abortion-related care, and discourage physicians from practicing in Florida. The bill was heard with multiple public comments, but the transcript excerpt does not show a final vote on SB 1284.

Transcript Highlights:

• As Kim mentioned, my name is Jen Amshai, and I have the pleasure of working in clinical laboratory and
• For those who don't know, the clinical lab is actually one of the most highly regulated areas in health
• So we can get the information to that physician to help make those clinical decisions that impact that
• patient the most when they have... ...those clinical decisions that impact that patient the most when
• Their drug trials are often, you know, most likely tested on a certain type of person.

Committee: House House Artificial Intelligence & Innovation Committee of Reference

Summary: The committee began with a lengthy informational presentation from Sonora Quest Laboratories on how it is using artificial intelligence and innovation in laboratory medicine. Company leaders described current and planned uses of AI in digital pathology, digital cytology, predictive analytics, genomics, sepsis markers, pharmacogenomics, and “digital twin” modeling for treatment planning and drug trials. They emphasized that their systems are kept in a closed, secure ecosystem, that human experts remain in the loop for validation, and that AI is being used to improve accuracy, speed, and productivity rather than replace workers. Members asked about specimen handling, safeguards against incorrect AI outputs, data security, expansion into hospital labs, and whether AI could help with precision medicine, rare diseases, and reducing step therapy; the presenters said AI could improve diagnosis and tailor treatment, but stressed ongoing human review and regulatory controls. The committee then took up Senate Bill 1786, which requires covered providers using generative AI to add provenance data to AI-created or significantly modified video, image, or audio content, using methods such as watermarking or metadata, with minor edits exempted. A Wilmot amendment was explained and adopted; it clarified the provenance requirements, added exceptions for certain interactive and non-user-generated media, protected trade secrets and confidential AI design information, and delayed the effective date to February 1, 2027. Members discussed the bill’s consumer-protection purpose, concerns about misleading AI-generated media, possible Commerce Clause issues, and the scope of the covered-provider definition. One member raised a concern about undefined “user” language, while others supported the measure as a needed disclosure requirement in a fast-changing policy area. The committee voted to give SB 1786, as amended, a do pass recommendation. The amendment passed on voice vote, and the final roll call was 4 ayes, 2 nays, and 1 absent. The chair closed by thanking members for their work during the committee’s first year and noting the session’s collaborative tone.

Transcript Highlights:

• Both of those I have filed on behalf of the trial court.
• And if the case goes to a jury trial, it takes even longer.
• I was treated like a criminal without a trial. My character was misrepresented.
• I oversee a legal clinic for the homeless and those reentering society from incarceration.
• One of the clinics that I provide, so I'm here in support of Senate Bill 1114, and I'm...

Committee: Joint Joint Committee on the Judiciary

Keywords: 995, all

Summary: The committee heard extensive testimony on several Judiciary bills, with the largest portion focused on S. 1178/H. 2052 to reduce mass incarceration and end life without parole. People incarcerated at MCI Framingham, MCI Norfolk, and NCCI Gardner described personal growth, rehabilitation, restorative justice work, family separation, and the belief that parole eligibility after long sentences would better reflect public safety and human development. Speakers emphasized that life without parole removes hope and can undermine rehabilitation, while supporters argued that many lifers are older, less likely to reoffend, and could contribute positively if given a chance at parole review. Committee members did not take votes during the hearing. The committee also heard testimony on S. 1139 to restore the statute of limitations for wrongful death claims involving tobacco use, with Sen. Keenan explaining that a recent SJC decision had cut off claims where the injured person did not sue within three years before death. He said the bill would restore families’ ability to seek redress in cases involving long-latency tobacco harms like COPD. Another major topic was S. 1205, which would add abusive litigation to the definition of coercive control in domestic violence law; Sen. Michael Moore said the bill would stop abusers from using repeated court filings to harass and financially burden survivors. The committee also took up S. 1114 on automatic record sealing, with Sen. Friedman and others arguing that the current petition-based process is slow, burdensome, and disproportionately harms people with criminal records, especially Black and Latino residents. Testimony also supported H. 1965/S. 1132 on compensation for wrongful conviction, with advocates and sponsors describing a faster administrative claims process, transitional support, and higher compensation without the current cap. Sen. Payano testified for S. 1241 to expand educational programming for incarcerated emerging adults, saying education reduces recidivism and improves reentry outcomes. A substantial portion of the hearing focused on S. 2522, an update to Massachusetts’ shield law for reproductive and gender-affirming care. Sen. Friedman, the Attorney General’s office, and DPH Commissioner Robbie Goldstein said the bill is needed to strengthen protections against out-of-state legal attacks, protect patient and provider data, clarify enforcement authority, and add a state-level EMTALA-style emergency care requirement. Committee members asked detailed questions about prescription labeling, the prescription monitoring program, attorney discipline, custody and full faith and credit issues, and whether the bill’s enforcement language could create unintended limits or conflicts. The Attorney General’s office said it would provide follow-up written testimony on several technical questions.

Transcript Highlights:

• or a bench trial.
• or whether they elected to have either a bench trial or a jury trial.
• or a jury trial can I do one bench trial or a jury trial can I do one more<01:59:32.119><c> followup
• or the jury trial.
• He fought for two years, participating in clinical trials and receiving harsh rounds of chemotherapy.

Keywords: 928, house, all

Summary: The committee first heard House Bill 199, which would extend the statute of limitations for civil actions seeking damages from PFAS contamination from six years to 20 years. The prime sponsor and other supporters argued that PFAS contamination in southern New Hampshire has long-term and often delayed health and property impacts, making the current six-year period too short for victims to discover harm, connect it to exposure, and seek relief. Supporters described contamination in places such as Merrimack and surrounding communities, cited health concerns including cancer, developmental issues, and other illnesses, and said a longer period would better preserve legal rights while still requiring proof of causation. The Department of Environmental Services said it was not taking a position but acknowledged the contamination and ongoing work to address it. The Business and Industry Association opposed the bill, arguing that evidence becomes stale over time, memories and documents fade, and a longer window would make it harder to determine causation when other exposures or intervening factors may be involved. Committee members questioned both sides about causation, the difficulty of proving PFAS-related illness, and whether a 20-year period was necessary if a plaintiff already knows of the injury and its source. Supporters responded that PFAS effects can emerge slowly, that scientific understanding continues to develop, and that current knowledge is still incomplete. Opponents said the existing discovery rule already starts the clock when harm and causal connection are known, and that extending the period would reduce clarity and fairness in litigation. After testimony and questions, the chair closed the hearing on HB 199. The committee then opened House Bill 268 FN, which was described as a technical measure to confirm that the Board of Tax and Land Appeals may hold hearings in its Concord hearing rooms. The sponsor indicated the bill reflects current practice and does not require additional facilities. With only one witness listed and no apparent opposition, the discussion was brief and focused on why the authorization should be placed in statute rather than left to practice.

Transcript Highlights:

• </c> Hawaii immediate supported clinical Hawaii immediate supported clinical access<01:08:36.120><c>
• </c><01:20:16.159><c> for</c> which funds a silis cybin trial for which funds a silis cybin trial for
• So is this therapy, which I'm very supportive of, only available through a clinical trial, given its
• I'm confused by the pilot program and the clinical trial.
• So then, as a follow-up, you know, I used to work for a clinical trials program.

Committee: House Health

Keywords: 910, house, all

Summary: The Committee on Health heard testimony on several bills. On SB 1441, which would repeal the transfer of the Oahu Regional Health Care System from HHSC to the Department of Health, the Department of Health said it strongly supports the measure and requested clarifying amendments. HHSC/Oahu Region also supported the bill and said it had no objection to the department’s amendments. In response to questions, witnesses said the agencies have been working on an MOU to support transfers of long-term care patients to Leahi, with the current goal being about 10 to 15 patients, but transfers would occur only as space and staffing allow; one patient was reportedly being admitted at the time, and the process was described as slow and case-by-case. The committee then heard SB 1443 on payment rates for state hospital patients and related Department of Health services. The hospital administrator said the bill would allow rates above Medicaid for community or foster-home placements if patients cannot be placed at Leahi or elsewhere, and would set Medicaid-level reimbursement for outside medical services used by state hospital patients. He said at least one provider was interested in offering services at that rate and that the population involved is largely non-ambulatory long-term care patients. Members asked about availability and training, and the witness said special training could be provided. SB 1322, a broad mental health bill, drew mixed testimony. The Department of Law Enforcement supported giving crisis-intervention-trained officers more discretion to transport people to medical care instead of arresting them. The Attorney General supported the bill but recommended revisions to emergency-transport language and restoring liability protections. HHSC and Queens Hospital supported the overall goal but sought amendments to preserve the mental health emergency worker role in decision-making and to avoid negative impacts on emergency departments. The Disability Rights Center and ACLU opposed parts of the bill, arguing that it weakens due process, reduces protections in involuntary treatment and transport, and should retain a three-person treatment panel rather than reduce it to one. A Queens representative said the current program works well and reported that more than 90% of MH1 cases once went to hospitals, but that figure has dropped to about 60-70%, with about 20% now diverted to community settings or the behavioral health crisis center. No votes or final committee actions were taken in the portion provided.

Transcript Highlights:

• These medications have been shown through rigorously designed long-term clinical trials to be highly
• </c> rigorously designed long-term clinical rigorously designed long-term clinical trials<00:36:52.960
• With these medications, the upper boundary for weight reduction according to the clinical trials is in
• <00:47:51.520><c> 22</c><00:47:52.400><c> 23</c><00:47:53.280><c> 24%</c> clinical trials is in the 22
• 23 24% clinical trials is in the 22 23 24% range.<00:47:55.280><c> So</c><00:47:55.520><c> we</c><00

Keywords: 958, all

Summary: The Medicaid Oversight and Advisory Board met on February 23, 2026, approved the January 12 minutes, and then focused primarily on Kentucky Medicaid’s coverage and potential expansion of GLP-1 drugs, especially for weight loss. Department for Medicaid Services Commissioner Lisa Lee explained that Medicaid currently does not cover drugs for weight loss, anorexia, or weight gain, but the department had filed a regulation to remove that blanket exclusion so GLP-1s could be covered when used for an underlying health condition. She said the administrative regulation review subcommittee found the regulation deficient, and the co-chairs wanted the board to discuss the policy and financing implications before any change. DMS also said it would be open to adding caveats to ensure coverage would not extend to cosmetic weight loss alone. The department provided several data points on current utilization and spending. In 2025, Kentucky Medicaid paid for appetite-stimulating drugs such as Megestrol, Dronabinol, and Marinol, but did not pay for weight-loss drugs. For GLP-1s, DMS said coverage began in 2025 and is limited to FDA-approved medical conditions, with prior authorization requiring a type 2 diabetes diagnosis code and A1C documentation. DMS reported $234.6 million in GLP-1 spending in 2025 before rebates, about 240,931 prescriptions, and said GLP-1s accounted for 7.3% of pharmacy spend in 2024 and 8.3% in 2025. It also said there were 24,844 expansion members and 13,638 non-expansion members using GLP-1s, with spending of about $156 million and $78.5 million respectively, and that 10 pediatric weight-loss prescriptions were covered under EPSDT. The department said outcome analyses, including whether GLP-1 use reduces insulin or other diabetes treatment, are underway and should be completed in a couple of months. Members asked about cost, rebates, and whether the state should wait for more outcomes data before expanding coverage. DMS said average reimbursement to pharmacies was $975 per prescription and the average dispensing fee was $109; it also said 2025 rebate invoices totaled $90.8 million, with $7.6 million collected so far. Several members expressed concern about the high cost and the need to evaluate whether the drugs improve health outcomes before expanding access, while others noted the potential benefits for obesity and diabetes treatment. Some members also discussed whether GLP-1s are effectively being used for weight loss in diabetic patients and whether broader data collection should be used to assess long-term value. After the Medicaid discussion, Eli Lilly executive Tracy Sims presented on obesity as a chronic disease and the economic burden it creates in Kentucky. She said Kentucky’s adult obesity rate is a little over 37%, that obesity is linked to about 200 diseases, and that untreated obesity costs the state billions in GDP and hundreds of millions in state budget impact. She highlighted recent federal access programs for GLP-1s, including a Medicaid-related program that she said could lower the state share of a Zepbound prescription to about $71 per month after federal matching. No votes were taken on the GLP-1 policy question during the meeting, and the main action was the receipt of testimony and discussion of the department’s proposed regulatory change.

Transcript Highlights:

• The clinic has to contact their insurance. It's a ding.
• They show up in our homes, in clinics, in communities long before They show up in our homes, in clinics
• clinic.
• clinic.
• We saw an abuser able to sue an abortion clinic, even though he drove his ex-wife to the clinic.

Keywords: 998, house, all

Transcript Highlights:

• Throughout my time in high school, I was involved in mock trial and the youth diversion program, giving
• And this furtherance of justice inquiry requires a trial court's ongoing exercise of discretion.”
• And this furtherance of justice inquiry requires a trial court's ongoing exercise of discretion.
• The clinic focuses on addressing systemic. the University of San Francisco's racial justice clinic.
• I testified in the trial where he was convicted and sentenced to life.

Summary: The committee heard a large public safety agenda and began by announcing several bills off calendar and limiting testimony to two witnesses per side. The first major item was AB 2698, which would authorize local governments to create youth court diversion programs for first-time juvenile offenders. The author and supporters, including Bakersfield Police Department representatives and a student participant, described the program as restorative, record-clearing, and successful in Bakersfield. Opponents argued it was not true diversion because it occurs after adjudication, could widen system involvement, and should instead be replaced by pre-arrest community-based diversion. The bill was moved on a due pass motion to Appropriations, but remained on call with some members not voting. The committee also adopted a consent calendar of ten bills without opposition. The committee then heard AB 1959, which would create a narrow exception allowing resentencing in adult court for certain violent juvenile offenders in a case arising from the Santana High School shooting. The author, San Diego County District Attorney Summer Stephan, and a survivor/city councilmember argued the bill would close a loophole that could lead to resentencing and early release despite parole denials. Several organizations registered opposition or opposed unless amended, but many noted they were reviewing the amended version. The bill was moved due pass as amended to Appropriations and remained on call. AB 1628, extending California’s safe surrender window for newborns from 72 hours to 30 days, drew broad support from the author, firefighters, medical and child welfare groups, and no opposition; it was moved due pass to Human Services and remained on call. The committee also approved AB 1974, which authorizes law enforcement agencies to create voluntary temporary firearm storage programs. The author and supporters from San Francisco law enforcement, Giffords, and gun safety groups said the bill would expand safe storage options during crises and in custody disputes; there was no opposition, and it passed due pass as amended. AB 2297, requiring restitution in diversion cases, drew support from the author, district attorneys, and victims’ advocates, while opponents argued it was duplicative, could burden low-income participants, and might undermine diversion success. After discussion about restitution law and ability to pay, the bill passed due pass. Finally, AB 2438, which would require people sentenced to more than six years to serve in state prison rather than county jail, drew support from the author and Riverside County Sheriff Bianco, who said realignment had overcrowded county jails and strained resources. Opponents warned it could worsen state prison overcrowding and conflict with realignment’s purpose. The chair recommended no, and the bill was moved due pass and re-refer to Appropriations, remaining on call.